Fideuram Asset Management Ireland dac Buys Shares of 99,871 Gilead Sciences, Inc. $GILD

Key Points

• Fideuram Asset Management Ireland dac disclosed a new fourth-quarter stake in Gilead Sciences, buying 99,871 shares worth about $12.0 million. The position makes Gilead its 24th-largest holding and about 0.9% of its portfolio.
• Gilead reported better-than-expected quarterly results, with EPS of $2.03 versus $1.91 estimated and revenue of $6.96 billion, up 4.4% year over year. The company also announced a quarterly dividend of $0.82 per share, yielding about 2.4%.
• Several insiders sold shares recently, including CEO Daniel O’Day and insider Johanna Mercier, while analysts remain broadly positive. Gilead has a consensus rating of Moderate Buy and an average price target of $156.93.

Fideuram Asset Management Ireland dac bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 99,871 shares of the biopharmaceutical company's stock, valued at approximately $12,030,000. Gilead Sciences comprises approximately 0.9% of Fideuram Asset Management Ireland dac's holdings, making the stock its 24th largest position.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $28,000. Financial Consulate Inc. grew its position in shares of Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 109 shares during the period. North Star Investment Management Corp. grew its position in shares of Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 86 shares during the period. MTM Investment Management LLC grew its position in shares of Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 176 shares during the period. Finally, BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares of the company's stock, valued at $81,702,353.72. The trade was a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 53,000 shares of company stock worth $7,075,670 in the last three months. 0.30% of the stock is owned by company insiders.

Gilead Sciences Trading Up 1.9%

Shares of NASDAQ:GILD opened at $136.22 on Friday. The stock has a 50 day moving average of $135.43 and a 200 day moving average of $134.08. The company has a market cap of $169.13 billion, a PE ratio of 18.56 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $104.46 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm's revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date is Monday, June 15th. Gilead Sciences's dividend payout ratio is presently 44.69%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent research reports. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price objective for the company in a research report on Wednesday, May 20th. Scotiabank boosted their price objective on Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a research note on Wednesday, February 11th. TD Cowen boosted their price objective on Gilead Sciences from $145.00 to $160.00 and gave the company a "buy" rating in a research note on Wednesday, February 11th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a "neutral" rating in a research note on Friday, April 17th. Finally, Wells Fargo & Company boosted their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a research note on Wednesday, February 11th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and a consensus target price of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.